Literature DB >> 3458697

Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis.

E Dournon, P Rajagopalan, J L Vilde, J J Pocidalo.   

Abstract

Pefloxacin was compared to erythromycin in the treatment of guinea pigs severely infected with Legionella pneumophila. In this experimental model, two single intraperitoneal injections of either pefloxacin (10 mg/kg at 48 h and 5 mg/kg at 55 h) or erythromycin (40 mg/kg at 48 and 55 h) were administered 48 h post-infection (2 X 10(7) virulent L. pneumophila intraperitoneally). Counts of bacteria in blood monocytes and lungs of animals killed at different times after the completion of treatment, demonstrated a quick and highly significant reduction of the pretreatment bacterial load in pefloxacin-treated guinea pigs. Conversely, in erythromycin-treated animals the number of bacteria was only slightly reduced 17 h after the completion of the treatment and then multiplication up to pre-treatment levels occurred. The overall mortality was significantly lower in pefloxacin-treated animals with this therapeutic protocol. The remarkable results of pefloxacin in this model, were obtained with serum and lung levels of this drug lower than those achieved in man with the currently accepted regimens. Thus, pefloxacin appears to be a new promising antimicrobial agent for Legionnaire's disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3458697     DOI: 10.1093/jac/17.suppl_b.41

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

1.  Activity of temafloxacin against respiratory pathogens.

Authors:  R N Swanson; D J Hardy; D T Chu; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Weidenfeld; M B Dorr
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Direct activation of human monocyte-derived macrophages by a bacterial glycoprotein extract inhibits the intracellular multiplication of virulent Legionella pneumophila serogroup 1.

Authors:  P Rajagopalan; E Dournon; J L Vildé; J J Pocidalo
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

4.  Efficacy of NY-198 against experimental Legionnaires disease.

Authors:  S Kohno; K Yamaguchi; Y Dohtsu; H Koga; T Hayashi; M Hirota; A Saito; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Authors:  T Schülin; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 6.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

7.  In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Ren; R Polzer; R P Gladue
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 9.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

10.  Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1.

Authors:  P Rajagopalan-Levasseur; E Dournon; G Dameron; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.